發(fā)布時間：2018-12-30 15:39

【摘要】：目的研究西蘭司瓊對腸易激綜合征(IBS)的臨床治療效果,探討西蘭司瓊治療IBS的機制。方法選取2014年7月-2015年10月在該院就診的IBS患者80例,隨機分為兩組:觀察組46例(口服西蘭司瓊8 mg,3次/d,連續(xù)服用6 d)、對照組34例(口服維生素C片50 mg,3次/d,連續(xù)服用6 d)。運用羅馬Ⅲ標準對治療結果進行評價,并運用免疫組織化學法分別測定回盲部黏膜肥大細胞(MC)數(shù)目、脫顆粒比率及高效液相電化學法測定5-HT濃度,記錄治療過程中的不良反應及不良反應率。結果治療后,觀察組顯效率和總有效率與對照組比較,差異均有統(tǒng)計學意義(P0.05),觀察組患者的MC數(shù)目和MC脫顆粒比率較對照組均減少,差異有統(tǒng)計學意義(P0.05),觀察組患者5-HT濃度恢復正常,且高于對照組(P0.05);治療前后治療組患者MC數(shù)目,MC脫顆粒比率以及5-HT濃度下降值均高于對照組(P0.05)。結論西蘭司瓊對IBS癥狀具有治療作用,可降低回盲部黏膜MC數(shù)目及脫顆粒比例,并可能通過與調(diào)節(jié)5-HT信號通路,來調(diào)節(jié)腸道運動有關。
[Abstract]:Objective to study the clinical effect of cilansetron on irritable bowel syndrome (IBS) and to explore the mechanism of cilansetron in the treatment of IBS. Methods Eighty patients with IBS from July 2014 to October 2015 were randomly divided into two groups: the observation group (n = 46) (oral cilanisetron 8 mg,3 / d) and the control group (n = 34) who took 6 d), orally for 50 mg,. 3 times / d, 6 d). The results of treatment were evaluated by Rome 鈪，

本文編號：2395771